Literature DB >> 24286142

The role for adjuvant radiotherapy in the treatment of hemangiopericytoma: a Surveillance, Epidemiology, and End Results analysis.

Adam M Sonabend1, Brad E Zacharia, Hannah Goldstein, Samuel S Bruce, Dawn Hershman, Alfred I Neugut, Jeffrey N Bruce.   

Abstract

OBJECT: Central nervous system (CNS) hemangiopericytomas are relatively uncommon and unique among CNS tumors as they can originate from or develop metastases outside of the CNS. Significant difference of opinion exists in the management of these lesions, as current treatment paradigms are based on limited clinical experience and single-institution series. Given these limitations and the absence of prospective clinical trials within the literature, nationwide registries have the potential to provide unique insight into the efficacy of various therapies.
METHODS: The authors queried the Surveillance Epidemiology and End Results (SEER) database to investigate the clinical behavior and prognostic factors for hemangiopericytomas originating within the CNS during the years 2000-2009. The SEER survival data were adjusted for demographic factors including age, sex, and race. Univariate and multivariate analyses were performed to identify characteristics associated with overall survival.
RESULTS: The authors identified 227 patients with a diagnosis of CNS hemangiopericytoma. The median length of follow-up was 34 months (interquartile range 11-63 months). Median survival was not reached, but the 5-year survival rate was 83%. Univariate analysis showed that age and radiation therapy were significantly associated with survival. Moreover, young age and supratentorial location were significantly associated with survival on multivariate analysis. Most importantly, multivariate analysis using the Cox proportional hazards model showed a statistically significant survival benefit for patients treated with gross-total resection (GTR) in combination with adjuvant radiation treatment (HR 0.31 [95% CI 0.01-0.95], p = 0.04), an effect not appreciated with GTR alone.
CONCLUSIONS: The authors describe the epidemiology of CNS hemangiopericytomas in a large, national cancer database, evaluating the effectiveness of various treatment paradigms used in clinical practice. In this study, an overall survival benefit was found when GTR was accomplished and combined with radiation therapy. This finding has not been appreciated in previous series of patients with CNS hemangiopericytoma and warrants future investigations into the role of upfront adjuvant radiation therapy.

Entities:  

Mesh:

Year:  2013        PMID: 24286142     DOI: 10.3171/2013.10.JNS13113

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  19 in total

Review 1.  Tumor-Induced Osteomalacia: an Up-to-Date Review.

Authors:  Anke H Hautmann; Matthias G Hautmann; Oliver Kölbl; Wolfgang Herr; Martin Fleck
Journal:  Curr Rheumatol Rep       Date:  2015-06       Impact factor: 4.592

2.  Invasiveness is associated with metastasis and decreased survival in hemangiopericytoma of the central nervous system.

Authors:  Connor J Kinslow; Raj S Rajpara; Cheng-Chia Wu; Samuel S Bruce; Peter D Canoll; Shih-Hsiu Wang; Adam M Sonabend; Sameer A Sheth; Guy M McKhann; Michael B Sisti; Jeffrey N Bruce; Tony J C Wang
Journal:  J Neurooncol       Date:  2017-04-26       Impact factor: 4.130

3.  Solitary-fibrous tumor/hemangiopericytoma of the central nervous system: a population-based study.

Authors:  Connor J Kinslow; Samuel S Bruce; Ali I Rae; Sameer A Sheth; Guy M McKhann; Michael B Sisti; Jeffrey N Bruce; Adam M Sonabend; Tony J C Wang
Journal:  J Neurooncol       Date:  2018-02-09       Impact factor: 4.130

4.  Epidemiology for primary brain tumors: a nationwide population-based study.

Authors:  Amélie Darlix; Sonia Zouaoui; Valérie Rigau; Faiza Bessaoud; Dominique Figarella-Branger; Hélène Mathieu-Daudé; Brigitte Trétarre; Fabienne Bauchet; Hugues Duffau; Luc Taillandier; Luc Bauchet
Journal:  J Neurooncol       Date:  2016-11-16       Impact factor: 4.130

5.  Efficacy of adjuvant radiotherapy in the intracranial hemangiopericytoma.

Authors:  Seung Hyuck Jeon; Sung-Hye Park; Jin Wook Kim; Chul-Kee Park; Sun Ha Paek; Il Han Kim
Journal:  J Neurooncol       Date:  2018-01-11       Impact factor: 4.130

6.  Sacral solitary fibrous tumour: surgery and hadrontherapy, a combined treatment strategy.

Authors:  Cesare Zoia; Francesco Lombardi; Maria Rosaria Fiore; Andrea Montalbetti; Alberto Iannalfi; Mattia Sansone; Daniele Bongetta; Francesca Valvo; Mattia Del Maestro; Sabino Luzzi; Renato Juan Galzio
Journal:  Rep Pract Oncol Radiother       Date:  2020-01-28

7.  The impact of postoperative radiation therapy on patterns of failure and survival improvement in patients with intracranial hemangiopericytoma.

Authors:  Eun Jung Lee; Jeong Hoon Kim; Eun Suk Park; Shin Kwang Khang; Young Hyun Cho; Seok Ho Hong; Chang Jin Kim
Journal:  J Neurooncol       Date:  2015-12-31       Impact factor: 4.130

8.  Pediatric choroid plexus tumors: epidemiology, treatments, and outcome analysis on 202 children from the SEER database.

Authors:  Roy W R Dudley; Michelle R Torok; Danielle Gallegos; Arthur K Liu; Michael H Handler; Todd C Hankinson
Journal:  J Neurooncol       Date:  2014-10-09       Impact factor: 4.130

9.  Spinal location is prognostic of survival for solitary-fibrous tumor/hemangiopericytoma of the central nervous system.

Authors:  Deborah Boyett; Connor J Kinslow; Samuel S Bruce; Adam M Sonabend; Ali I Rae; Guy M McKhann; Michael B Sisti; Jeffrey N Bruce; Simon K Cheng; Tony J C Wang
Journal:  J Neurooncol       Date:  2019-05-03       Impact factor: 4.130

Review 10.  Radiation therapy strategies for skull-base malignancies.

Authors:  J D Palmer; M E Gamez; K Ranta; H Ruiz-Garcia; J L Peterson; D M Blakaj; D Prevedello; R Carrau; A Mahajan; K L Chaichana; D M Trifiletti
Journal:  J Neurooncol       Date:  2020-08-12       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.